JP6576941B2 - 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 - Google Patents

骨髄異形成症候群の治療のためのｊａｋ１阻害剤 Download PDF

Info

Publication number
JP6576941B2
JP6576941B2 JP2016554471A JP2016554471A JP6576941B2 JP 6576941 B2 JP6576941 B2 JP 6576941B2 JP 2016554471 A JP2016554471 A JP 2016554471A JP 2016554471 A JP2016554471 A JP 2016554471A JP 6576941 B2 JP6576941 B2 JP 6576941B2
Authority
JP
Japan
Prior art keywords
pyrrolo
pyrimidin
pyrazol
trifluoromethyl
myelodysplastic syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016554471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506659A5 (cg-RX-API-DMAC7.html
JP2017506659A (ja
Inventor
クリシュナ・ヴァディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2017506659A publication Critical patent/JP2017506659A/ja
Publication of JP2017506659A5 publication Critical patent/JP2017506659A5/ja
Application granted granted Critical
Publication of JP6576941B2 publication Critical patent/JP6576941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016554471A 2014-02-28 2015-02-27 骨髄異形成症候群の治療のためのｊａｋ１阻害剤 Active JP6576941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946124P 2014-02-28 2014-02-28
US61/946,124 2014-02-28
PCT/US2015/017963 WO2015131031A1 (en) 2014-02-28 2015-02-27 Jak1 inhibitors for the treatment of myelodysplastic syndromes

Publications (3)

Publication Number Publication Date
JP2017506659A JP2017506659A (ja) 2017-03-09
JP2017506659A5 JP2017506659A5 (cg-RX-API-DMAC7.html) 2018-04-12
JP6576941B2 true JP6576941B2 (ja) 2019-09-18

Family

ID=52693052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554471A Active JP6576941B2 (ja) 2014-02-28 2015-02-27 骨髄異形成症候群の治療のためのｊａｋ１阻害剤

Country Status (29)

Country Link
US (4) US20150246046A1 (cg-RX-API-DMAC7.html)
EP (1) EP3110409B1 (cg-RX-API-DMAC7.html)
JP (1) JP6576941B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160136323A (cg-RX-API-DMAC7.html)
CN (2) CN112494652A (cg-RX-API-DMAC7.html)
AU (1) AU2015222913B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940659C (cg-RX-API-DMAC7.html)
CL (1) CL2016002144A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160449A (cg-RX-API-DMAC7.html)
CY (1) CY1120857T1 (cg-RX-API-DMAC7.html)
DK (1) DK3110409T3 (cg-RX-API-DMAC7.html)
EA (1) EA201691745A1 (cg-RX-API-DMAC7.html)
ES (1) ES2688553T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181661T1 (cg-RX-API-DMAC7.html)
HU (1) HUE041456T2 (cg-RX-API-DMAC7.html)
IL (1) IL247475B (cg-RX-API-DMAC7.html)
LT (1) LT3110409T (cg-RX-API-DMAC7.html)
MX (1) MX372939B (cg-RX-API-DMAC7.html)
MY (1) MY185392A (cg-RX-API-DMAC7.html)
PE (1) PE20161388A1 (cg-RX-API-DMAC7.html)
PL (1) PL3110409T3 (cg-RX-API-DMAC7.html)
PT (1) PT3110409T (cg-RX-API-DMAC7.html)
RS (1) RS57723B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201607083VA (cg-RX-API-DMAC7.html)
SI (1) SI3110409T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800551T1 (cg-RX-API-DMAC7.html)
UA (1) UA121857C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015131031A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606610B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20120371A1 (es) 2009-05-22 2012-05-17 Incyte Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4il)-1h-pirazol-1-il]octano o heptano-nitrilo como inhibidores de jak
DK3354652T3 (da) 2010-03-10 2020-05-18 Incyte Holdings Corp Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR093308A1 (es) 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
SMT201900081T1 (it) 2013-03-06 2019-05-10 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
PE20200527A1 (es) 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak
HRP20200955T1 (hr) 2013-08-07 2020-10-02 Incyte Corporation Dozni oblici s produženim oslobađanjem za jak1 inhibitor
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
NZ763326A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
PE20170300A1 (es) 2014-04-30 2017-04-19 Incyte Corp Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN109072190A (zh) * 2016-03-09 2018-12-21 蔚山大学校产学协力团 将jak1抑制剂作为有效成分包含的用于干细胞的增殖、分化促进或老化抑制的组成物
KR101934107B1 (ko) * 2016-12-15 2018-12-31 가톨릭대학교산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물
KR102485731B1 (ko) 2017-01-23 2023-01-05 상하이 롱우드 바이오파마슈티칼스 컴퍼니 리미티드 Jak 효소 억제제 및 이의 제조 방법과 용도
CN109867676B (zh) * 2017-12-01 2020-10-30 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
IL276302B2 (en) 2018-01-30 2023-11-01 Incyte Corp Procedures for preparing [1-(3-fluoro-2-(trifluoromethyl(isonicotinyl}piperidine-4-one)
EP3746149B1 (en) 2018-02-01 2025-08-06 Shifamed Holdings, LLC Intravascular blood pumps
KR20240157777A (ko) 2018-02-16 2024-11-01 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公司 用于移植物抗宿主病的生物标志物
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
EA202191170A1 (ru) * 2018-10-31 2021-07-27 Инсайт Корпорейшн Комбинированная терапия для лечения гематологических заболеваний
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
IL285999B1 (en) * 2019-03-05 2025-09-01 Incyte Corp JAK1 inhibitor pathway for the treatment of chronic lung allograft dysfunction
AU2020356575A1 (en) 2019-09-27 2022-04-14 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN111358791A (zh) * 2020-03-13 2020-07-03 深圳百奥捷生物科技有限公司 Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用
BR112022024632A2 (pt) 2020-06-02 2023-02-28 Incyte Corp Processos para preparar um inibidor de jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
US20240091215A1 (en) * 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
CA3219092A1 (en) 2021-05-03 2022-11-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2002215608B2 (en) 2000-06-28 2004-12-09 Smithkline Beecham P.L.C. Wet milling process
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
CN1582150B (zh) 2001-10-30 2011-09-07 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
UA116187C2 (uk) * 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
NZ587928A (en) 2008-03-11 2012-08-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK3354652T3 (da) * 2010-03-10 2020-05-18 Incyte Holdings Corp Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) * 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US20140073643A1 (en) * 2010-12-03 2014-03-13 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
AR086983A1 (es) * 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) * 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
US10155987B2 (en) * 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
AR093308A1 (es) * 2012-11-01 2015-05-27 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
PE20200527A1 (es) * 2013-05-17 2020-03-09 Incyte Corp Derivados del bipirazol como inhibidores jak

Also Published As

Publication number Publication date
BR112016019511A8 (pt) 2023-01-24
CA2940659A1 (en) 2015-09-03
CA2940659C (en) 2023-01-03
US20220378791A1 (en) 2022-12-01
NZ724464A (en) 2021-01-29
MY185392A (en) 2021-05-17
EA201691745A1 (ru) 2016-12-30
AU2015222913B2 (en) 2019-12-12
CY1120857T1 (el) 2019-12-11
SMT201800551T1 (it) 2019-01-11
DK3110409T3 (en) 2018-10-22
MX372939B (es) 2020-04-03
IL247475B (en) 2020-05-31
PL3110409T3 (pl) 2018-12-31
IL247475A0 (en) 2016-11-30
CR20160449A (es) 2016-12-20
AU2015222913A1 (en) 2016-09-29
WO2015131031A1 (en) 2015-09-03
KR20160136323A (ko) 2016-11-29
CN112494652A (zh) 2021-03-16
EP3110409B1 (en) 2018-08-15
UA121857C2 (uk) 2020-08-10
CN106456773A (zh) 2017-02-22
SG11201607083VA (en) 2016-09-29
HUE041456T2 (hu) 2019-05-28
US20190111058A1 (en) 2019-04-18
SG10201807952PA (en) 2018-10-30
PT3110409T (pt) 2018-11-07
ZA201606610B (en) 2020-08-26
LT3110409T (lt) 2019-01-25
SI3110409T1 (sl) 2018-11-30
PE20161388A1 (es) 2016-12-28
ES2688553T3 (es) 2018-11-05
CL2016002144A1 (es) 2016-12-16
US20210069193A1 (en) 2021-03-11
MX2016011103A (es) 2017-02-28
US20150246046A1 (en) 2015-09-03
JP2017506659A (ja) 2017-03-09
HRP20181661T1 (hr) 2018-12-14
BR112016019511A2 (cg-RX-API-DMAC7.html) 2017-08-15
RS57723B1 (sr) 2018-12-31
EP3110409A1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
JP6576941B2 (ja) 骨髄異形成症候群の治療のためのｊａｋ１阻害剤
JP7012534B2 (ja) 癌および自己免疫疾患を治療するための最適化された組合せ療法およびその使用
JP6242885B2 (ja) ５−アザインダゾール化合物及び使用方法
JP7399968B2 (ja) Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
CA2814419A1 (en) Cxcr4 receptor antagonists
CA2921568A1 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
KR102524622B1 (ko) Ｎｉｋ 억제제로서의 신규 티에노피리미딘 유도체
JP6916796B2 (ja) Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体
RS54823B1 (sr) Derivati piperidin-4-il azetidina kao inhibitori jak1
EP3464267B1 (en) New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
WO2018127195A1 (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
JP2024500378A (ja) 多環状ｉｒａｋ及びｆｌｔ３阻害化合物、並びにその使用
US11161838B2 (en) Heterocyclic derivatives as PI3K inhibitors
EP3691642B1 (en) [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
JP2023503322A (ja) Ｄｕｘ４発現に関連する疾患を処置するための新規化合物
HK1231762A1 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
HK1231762B (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
EA040337B1 (ru) Ингибиторы jak1 для лечения миелодиспластических синдромов
BR112016019511B1 (pt) Uso de inibidores de jak1 para o tratamento de síndromes mielodisplásicas
NZ724464B2 (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
JP2023503988A (ja) Ｄｕｘ４発現に関連する疾患を処置するための新たな化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190821

R150 Certificate of patent or registration of utility model

Ref document number: 6576941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250